Peregrine Pharmaceuticals Earnings Preview: Can This Streak Continue?

Peregrine Pharmaceuticals (NASDAQ:PPHM) will report earnings after markets close on Thursday, July 11th. Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the research, development and commercialization of novel therapeutics for cancer and a wide range of viral diseases.

Here is your Cheat Sheet to Peregrine Pharmaceuticals Earnings:

Earnings Expectations: Analysts expect earnings of $-0.06 per share on revenues of $3.57 million.

Analyst Trends:

Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a loss of $0.05 and has not changed. For the current year, the average estimate is a loss of $0.23, which is the same as the estimate ninety days ago.

Earnings Trends:

Here’s how Peregrine Pharmaceuticals has been performing on an annual basis:

Fiscal Year 2009 2010 2011 2012
Revenue ($) in millions 18 28 13 15
Diluted EPS ($) -0.35 -0.30 -0.56 -0.50

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Apr. 30, 2012 Jul. 31, 2012 Oct. 31, 2012 Jan. 31, 2013
Revenue ($) in millions 2.07 4.25 6.14 7.04
Diluted EPS ($) -0.10 -0.07 -0.08 -0.04

Past Performance:
Peregrine Pharmaceuticals has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]